Thymosin Alpha-1 Tracker App
Log Clinical and Research Doses, Monitor Immune Labs, and Track T Cell Response
Thymosin Alpha-1 (Ta1) is a 28-amino-acid thymic peptide that acts as a potent modulator of adaptive and innate immune function — increasing T cell maturation, NK cell activity, dendritic cell activation, and cytokine balance. Unlike most peptides on this list, Thymosin Alpha-1 has received clinical approval in some countries under the brand name Zadaxin (SciClone Pharmaceuticals) for hepatitis B and hepatitis C treatment in immunocompromised patients. Shotlee tracks your dose logs, immune lab results, infection frequency, and cycle progress in one free app.
What Is Thymosin Alpha-1?
Thymosin Alpha-1 is the N-terminal fragment of thymosin fraction 5, a thymic hormone complex first isolated in the 1970s by Allan Goldstein. It is a 28-amino-acid peptide that has since been identified as the primary immunologically active component of the thymic fraction, driving T cell precursor maturation into functional T helper and cytotoxic T cells in the thymus and periphery.
Thymosin Alpha-1 is the only peptide on the immune tracker list with formal clinical approvals: Zadaxin is approved in over 35 countries — including throughout Asia and parts of Europe — for hepatitis B, hepatitis C, and as an adjunct therapy in immunocompromised patients. Clinical trials have also studied it in the context of sepsis, COVID-19 severity reduction, and as a vaccine adjuvant. Its unique regulatory standing makes it the most clinically validated compound in the immune peptide category.
Protocol Options
Standard clinical dosing used in Zadaxin hepatitis B and C trials. Two injections per week, typically for 6–12 months in chronic viral hepatitis protocols.
Higher-frequency research protocol for general immune support, chronic infection, or adjunct use. Daily dosing used in some COVID-19 and sepsis adjunct studies.
Clinical Research Highlights
Mechanism of Action
What to Track in Shotlee
Build a comprehensive immune monitoring record — doses, T cell counts, NK activity, infection frequency, and energy.
Thymosin Alpha-1 vs Thymosin Beta-4 (TB-500): Understanding the Difference
Despite sharing the "Thymosin" name, Thymosin Alpha-1 and Thymosin Beta-4 (TB-500) are structurally unrelated and act through completely different mechanisms. Thymosin Alpha-1 is an immune modulator — its therapeutic target is the immune system (T cells, NK cells, dendritic cells). TB-500 is a tissue repair peptide — its target is actin-mediated cell migration, muscle and tendon healing.
Some advanced protocols combine both: TB-500 for structural tissue repair and Thymosin Alpha-1 for immune support during recovery or chronic illness. If stacking, log each compound separately in Shotlee to clearly attribute effects and avoid confounding your clinical data.
Protocol FAQs
Thymosin Alpha-1 (Zadaxin) is clinically approved in over 35 countries for chronic hepatitis B and C, and for immune support in immunocompromised patients. Research applications include chronic infections, sepsis adjunct therapy, COVID-19 severity reduction, and cancer immunotherapy adjunct. Track your protocol in Shotlee.
The standard clinical Zadaxin dose is 1.6 mg subcutaneously twice weekly. Clinical hepatitis protocols typically run for 6–12 months. Research protocols for general immune support may use 900 mcg daily. Always follow physician guidance for clinical indications.
As of 2026, Thymosin Alpha-1 (Zadaxin) is not FDA-approved in the United States. However, it is approved in over 35 other countries, including throughout Asia and parts of Europe, for hepatitis B, hepatitis C, and immunocompromised patient management. It is the most clinically validated immune peptide in this category.
Priority labs include CD4/CD8 T cell counts and ratio, NK cell percentage, lymphocyte subsets, and for hepatitis patients, HBV/HCV viral load, ALT, and AST. Log all values with dates in Shotlee to build a longitudinal immune monitoring record.
No. Despite sharing the Thymosin name, they are structurally unrelated peptides with completely different mechanisms. Thymosin Alpha-1 is an immune modulator targeting T cell maturation and NK cell activity. Thymosin Beta-4 (TB-500) is an actin-binding tissue repair peptide. They act on entirely different biological systems.
Track Your Thymosin Alpha-1 Protocol in Shotlee
Log every dose, record immune labs, monitor infection frequency, and track your adaptive immune response — all free in Shotlee.